NCT04144569

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Yongchang Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer

Conditions

• HER2 Insertion Mutation Positive Advanced NSCLC

Interventions

Type	Name	Description
DRUG	PD-1 Combined With Pyrotinib	PD-1 Combined With Pyrotinib

Timeline

• Start date: 2019-01-30
• Primary completion: 2024-12-30
• Completion: 2024-12-31
• First posted: 2019-10-30
• Last updated: 2024-09-19

Locations

1 site across 1 country: China